3 withdrawn. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Withdrawn 3 |
Follow Benign Prostatic Hyperplasia: new trials by email Literature Review of Benign Prostatic Hyperplasia trials Research Report on Benign Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder Intravesical Botox injection - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Withdrawn | University Hospitals Cleveland Medical Center | 2026-06-01 | 2025-09-05 | |
| Role of Prophylactic Postoperative Antibiotics in HoLEP Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination - Benign Prostatic Hyperplasia, Urinary Tract Infections | Phase 4 | Withdrawn | Baylor Research Institute | 2023-03-01 | 2026-02-12 | |
| The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia selective alpha 1-blockers, celecoxib, alpha-blocker and NSAID - Benign Prostatic Hyperplasia | Phase 4 | Withdrawn | Samsung Medical Center | 2008-05-01 | 2013-06-10 |
Prostatic Hyperplasia (3) · Urinary Bladder, Overactive (1) · Urinary Tract Infections (1)
Genital Diseases (3) · Genital Diseases, Male (3) · Male Urogenital Diseases (3) · Prostatic Diseases (3) · Urogenital Diseases (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Urologic Diseases (2) · Infections (1) · Lower Urinary Tract Symptoms (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urinary Bladder Diseases (1) · Urological Manifestations (1)
Adrenergic alpha-Antagonists (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Celecoxib (1) · Cephalexin (1) · Ciprofloxacin (1) · Doxazosin (1) · Nitrofurantoin (1) · Tamsulosin (1) · Terazosin (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · alfuzosin (1)
Baylor Research Institute (1) · Samsung Medical Center (1) · University Hospitals Cleveland Medical Center (1)
United States (2) · South Korea (1)
Kyu-Sung Lee, Ph.D., M.D. (1) · Marawan M. El Tayeb, MD (1) · Michael Zell, MD (1)